AKT1 and cervical carcinoma: Cervical cancer patients are already subjects of (or included in) clinical trials testing PI3K/AKT/mTOR pathway inhibitors (e.g., NCT01958112, NCT01217177, NCT01026792, NCT01226316) [77].